2023-12-01 2024-11-30 false Capium Accounts Production 1.1 11669313 2023-12-01 2024-11-30 11669313 bus:AbridgedAccounts 2023-12-01 2024-11-30 11669313 bus:FRS102 2023-12-01 2024-11-30 11669313 bus:AuditExemptWithAccountantsReport 2023-12-01 2024-11-30 11669313 bus:SmallCompaniesRegimeForAccounts 2023-12-01 2024-11-30 11669313 bus:PrivateLimitedCompanyLtd 2023-12-01 2024-11-30 11669313 2023-12-01 2024-11-30 11669313 2024-11-30 11669313 bus:RegisteredOffice 2023-12-01 2024-11-30 11669313 core:WithinOneYear 2024-11-30 11669313 core:AfterOneYear 2024-11-30 11669313 1 2023-12-01 2024-11-30 11669313 bus:Director1 2023-12-01 2024-11-30 11669313 bus:Director1 2024-11-30 11669313 bus:Director1 2022-12-01 2023-11-30 11669313 bus:Director2 2023-12-01 2024-11-30 11669313 bus:Director2 2024-11-30 11669313 bus:Director2 2022-12-01 2023-11-30 11669313 bus:Director3 2023-12-01 2024-11-30 11669313 bus:Director3 2024-11-30 11669313 bus:Director3 2022-12-01 2023-11-30 11669313 bus:Director4 2023-12-01 2024-11-30 11669313 bus:Director4 2024-11-30 11669313 bus:Director4 2022-12-01 2023-11-30 11669313 bus:Director5 2023-12-01 2024-11-30 11669313 bus:Director5 2024-11-30 11669313 bus:Director5 2022-12-01 2023-11-30 11669313 2022-12-01 11669313 bus:LeadAgentIfApplicable 2023-12-01 2024-11-30 11669313 2022-12-01 2023-11-30 11669313 2023-11-30 11669313 core:WithinOneYear 2023-11-30 11669313 core:AfterOneYear 2023-11-30 11669313 bus:EntityAccountantsOrAuditors 2022-12-01 2023-11-30 11669313 core:NetGoodwill 2023-12-01 2024-11-30 11669313 core:NetGoodwill 2024-11-30 11669313 core:NetGoodwill 2023-11-30 11669313 core:CostValuation core:Non-currentFinancialInstruments 2024-11-30 11669313 core:CostValuation core:Non-currentFinancialInstruments 2023-11-30 11669313 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-11-30 11669313 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-11-30 11669313 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-11-30 11669313 core:Non-currentFinancialInstruments 2024-11-30 11669313 core:Non-currentFinancialInstruments 2023-11-30 11669313 core:ShareCapital 2024-11-30 11669313 core:ShareCapital 2023-11-30 11669313 core:RetainedEarningsAccumulatedLosses 2024-11-30 11669313 core:RetainedEarningsAccumulatedLosses 2023-11-30 11669313 dpl:Item1 2023-12-01 11669313 dpl:Item1 2024-11-30 11669313 dpl:Item1 2022-12-01 11669313 dpl:Item1 2023-11-30 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 11669313
JUNCTION PHARMA LIMITED
Abridged Accounts
Period of accounts Start date: 01 December 2023 End date: 30 November 2024

JUNCTION PHARMA LIMITED Contents Page For the year ended 30 November 2024
Accountants' report | 1
Statement of financial position | 2
Notes to the financial statements | 3

JUNCTION PHARMA LIMITED Accountants' Report For the year ended 30 November 2024
Accountant’s report You consider that the company is exempt from an audit for the year ended 30 November 2024 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year. In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us. We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts. Myrtle Gund Ltd 30 November 2024 .................................................... Myrtle Gund Ltd Red Ledge Business Centre 289-291 Huddersfield Road Holmfirth HD9 3UA 20 January 2026 1

JUNCTION PHARMA LIMITED Statement of Financial Position As at 30 November 2024
| Notes | 2024 £ |  | 2023 £
--- | --- | --- | --- | ---
Fixed assets |  |  |
Intangible fixed assets | 3 | 264,476 |  | 281,006
|  | 264,476 |  | 281,006
Current assets |  |  |
Stocks |  | 35,000 |  | 35,000
Debtors |  | 111,965 |  | 100,148
Cash at bank and in hand |  | 415,866 |  | 371,621
|  | 562,831 |  | 506,769
Creditors: amount falling due within one year |  | (356,656) |  | (350,672)
Net current assets |  | 206,175 |  | 156,097
Total assets less current liabilities |  | 470,651 |  | 437,103
Creditors: amount falling due after more than one year |  | (445,147) |  | (455,082)
Net assets |  | 25,504 |  | (17,979)
Capital and reserves |  |  |
Called up share capital |  | 100 |  | 100
Profit and loss account |  | 25,404 |  | (18,079)
Shareholders' funds |  | 25,504 |  | (17,979)
For the year ended 30 November 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Directors' responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A). The financial statements were approved by the board of directors on 20 January 2026 and were signed on its behalf by:
------------------------------- Toseef Ishtiaq Director
2

JUNCTION PHARMA LIMITED Notes to the Abridged Financial Statements For the year ended 30 November 2024
General Information JUNCTION PHARMA LIMITED is a private company, limited by shares, registered in , registration number 11669313, registration address 4 Batley Road, Heckmondwike, WF16 9NE. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies. The financial statements are prepared in sterling which is the functional currency of the company.
2. | Average number of employees Average number of employees during the year was 4 (2023 : 4).
3. | Intangible fixed assets
Cost | Goodwill |  | Total
| £ |  | £
At 01 December 2023 | 330,595 |  | 330,595
Additions | - |  | -
Disposals | - |  | -
At 30 November 2024 | 330,595 |  | 330,595
Amortisation
At 01 December 2023 | 49,589 |  | 49,589
Charge for year | 16,530 |  | 16,530
On disposals | - |  | -
At 30 November 2024 | 66,119 |  | 66,119
Net book values
At 30 November 2024 | 264,476 |  | 264,476
At 30 November 2023 | 281,006 |  | 281,006
3